REG - Hikma Pharmaceutical - Further re Colchicine Litigation <Origin Href="QuoteRef">HIK.L</Origin>

Hikma PharmaceuticalsAnnouncement

19/05/2016 12:20

RNS Number : 7584Y
Hikma Pharmaceuticals Plc
19 May 2016
Hikma wins Mitigare / Colchicine patent infringement case
London, 19 May 2016- Hikma Pharmaceuticals PLC (Hikma) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY), (rated Ba1 Moody's / BB+ S&P, both stable), the fast growing multinational pharmaceutical group, today announces that the United States District Court for the District of Delaware has ruled in favour of Hikma and its wholly-owned subsidiary in the United States, West-Ward Pharmaceutical Corp., by granting their motion to dismiss claims made by Takeda Pharmaceuticals USA, Inc. for alleged infringement of patents covering methods of use of Takeda's colchicine product, Colcrys. 
Since January 2015, Hikmahas been marketing its own colchicine product under the brand nameMitigare, as well as selling an authorised generic, increasing patient access to this important product in the United States.
Said Darwazah, Chairman and CEO of Hikma, said:
"I am very pleased with the ruling of the Delaware Court. This is a successful outcome and demonstrates our commitment to bringing more differentiated products to the US market."
-- ENDS --
Enquiries
Hikma Pharmaceuticals PLC 
Susan Ringdal, VP Corporate Strategy and Investor Relations +44 (0)20 7399 2760/ +44 7776 477050
Zeena Murad, Investor Relations Manager +44 (0) 20 7399 2768/ +44 7771 665277
FTI Consulting  
Ben Atwell/ Matthew Cole / Julia Phillips +44 (0)20 3727 1000
About Hikma
Hikma Pharmaceuticals PLC is a fast growing multinational group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products. Hikma operates through three businesses: "Injectables", "Branded" and "Generics", based principally in the United States, the Middle East and North Africa (MENA) and Europe. In 2015, Hikma achieved revenues of $1,440 million and profit attributable to shareholders of $252 million. 

This information is provided by RNS
The company news service from the London Stock Exchange
  END
FURAKCDDDBKDQPD